INSTITUT DE CARDIOLOGIE DE MONTREAL

Patent Applications and Registrations

Patent applications and USPTO patent grants for INSTITUT DE CARDIOLOGIE DE MONTREAL.The latest application filed is for "methods of treating elevated plasma cholesterol".

Company Profile

2.12.12

INSTITUT DE CARDIOLOGIE DE MONTREAL - Montreal NY CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Methods Of Treating Elevated Plasma Cholesterol App 20220296593 - BEREZOV; Alan ; et al.	2022-09-22
Early Administration Of Low-dose Colchicine After Myocardial Infarction App 20220249409 - TARDIF; Jean-Claude	2022-08-11
Early administration of low-dose colchicine after myocardial infarction Grant 11,400,063 - Tardif August 2, 2	2022-08-02
Targeting Senescent Cells App 20220135981 - THORIN; Eric	2022-05-05
Videomicroscopy of contractile cell cultures and cell culture methods using same. App 20210371804 - Belzil; Antoine ; et al.	2021-12-02
Pcsk9 Inhibitory Polypolypeptides And Methods Of Use App 20210162000 - Poirier; Steve ; et al.	2021-06-03
Early Administration Of Low-dose Colchicine After Myocardial Infarction App 20210145773 - TARDIF; Jean-Claude	2021-05-20
A Co-culture System And Method For In Vitro Assessment Of Reverse Cholesterol Transport App 20190284527 - RHAINDS; David ; et al.	2019-09-19
Pcsk9 Inhibitory Polypolypeptides And Methods Of Use App 20180207223 - Poirier; Steve ; et al.	2018-07-26
Genotyping Tests And Methods For Evaluating Plasma Creatine Kinase Levels App 20160230231 - Dube; Marie-Pierre ; et al.	2016-08-11
Pharmaceutical Compositions For The Treatment Of Left Ventricular Diastolic Dysfunction Comprising An Apolipoprotein Peptide/phospholipid Complex App 20150374675 - TARDIF; Jean-Claude ; et al.	2015-12-31
Pharmaceutical Compositions For The Treatment Of Left Ventricular Diastolic Dysfunction Comprising An Apolipoprotein Peptide/phospholipid Complex App 20140309426 - TARDIF; Jean-Claude ; et al.	2014-10-16
Labelled adrenomedullin derivatives and their use for imaging and therapy Grant 8,703,098 - Dupuis , et al. April 22, 2	2014-04-22
Genetic predictors of international normalized ratio (INR) fluctuation with warfarin therapy Grant 8,563,241 - Dube , et al. October 22, 2	2013-10-22
Labelled adrenomedullin derivatives and their use for imaging and therapy Grant 8,475,764 - Dupuis , et al. July 2, 2	2013-07-02
Method for detecting a biomarker of oxidative stress in a biological sample Grant 8,030,010 - Des Rosiers , et al. October 4, 2	2011-10-04
Method for quantifying oxidative stress caused by different biological pathways Grant 7,993,859 - Des Rosiers , et al. August 9, 2	2011-08-09
Angiopoietin-like 2 as a biomarker of vascular endothelial cell abnormal function and senescence Grant 7,972,795 - Thorin , et al. July 5, 2	2011-07-05
Method for assessing the contraction synchronization of a heart Grant 7,620,447 - Harel , et al. November 17, 2	2009-11-17
Labelled Adrenomedullin Derivatives and Their Use for Imaging and Therapy App 20080274050 - Dupuis; Jocelyn ; et al.	2008-11-06
Computation of a geometric parameter of a cardiac chamber from a cardiac tomography data set Grant 7,430,309 - Harel , et al. September 30, 2	2008-09-30
Antisense strategy to modulate estrogen receptor response (ER .alpha. and/or ER .beta. ) Grant 7,235,534 - Tanguay , et al. June 26, 2	2007-06-26
Non-invasive detection of endothelial dysfunction by blood flow measurement in opposed limbs using tracer injection Grant 6,445,945 - Arsenault September 3, 2	2002-09-03

Company Registrations

NCAGE Code	L6334	INSTITUT DE CARDIOLOGIE DE MONTREAL
CAGE Code	L6334	INSTITUT DE CARDIOLOGIE DE MONTREAL

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.